🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSOUL trial preliminary data — semaglutide in T2DM cardiovascular outcomes Page 4

SOUL trial preliminary data — semaglutide in T2DM cardiovascular outcomes

Dr.CardioMD Tue, Jun 2, 2026 at 1:06 AM 20 replies 546 viewsPage 4 of 4
FitDadDave
Member
534
2,678
Jul 2024
Minneapolis, MN
Jun 5, 2026 at 10:54 PM#16
PeptideChemSF said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.

Last edited: Jun 6, 2026 at 1:54 AM
47 22Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 44 others
Reply Quote Save Share Report
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Jun 6, 2026 at 1:51 PM#17
Dr.RaviCardio said:
Dr.CardioMD said: ...we don't know the long-term effects of cardiovascular risk...

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Taking it to my next appointment.

Last edited: Jun 6, 2026 at 7:51 PM
46 21pete_RVA, CarlaRPh_TPA, steph_laguna and 43 others
Reply Quote Save Share Report
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Jun 7, 2026 at 4:47 AM#18

From the other side of the consultation, briefly.

Dr.RaviCardio said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

Last edited: Jun 7, 2026 at 8:47 AM
45 20emma_london, tammy_FL, Dr.LipidDallas and 42 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Jun 7, 2026 at 7:43 PM#19
anna.melb_AU said:
Dr.RaviCardio said: ...cardiovascular risk is just another fad...

Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.

44 19Dr.PeteFamMed, claudia_zurich, nancy_portland and 41 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 8, 2026 at 10:39 AM#20

Moderator note: a couple of off-topic posts removed. Report rather than reply if it drifts again.

22 22PurityPaulOR, MaxMetOK, MounjBrad and 19 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register